Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (9): 1009-1012.

Previous Articles     Next Articles

Inhibitory effect of histone deacetylase inhibitor FK228 on LNCaP prostate cancer cells

SUN Sheng-kun1, HONG Bao-fa1, LI Xiu-shen2, HOU Chun-mei2, XIAO Xu-ren1, YU Xiao-dan2   

  1. 1Department of Urology, PLAGeneral Hospital, Beijing 100853, China;
    2Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China
  • Received:2007-05-17 Revised:2007-06-27 Online:2007-09-26 Published:2020-10-30

Abstract: AIM: To investigate the mechanisms underlying the antitumor effect of histone deacetylase inhibitor FK228 on LNCaP prostate cancer cell line.METHODS: Proliferation of LNCaP cells exposed to FK228 was detected by MTT assay.Cell apoptosis was assayed by hoechst 33342 nuclei staining.Cleaved PARP, an apoptosis marker protein, was assayed by western blotting after FK228 exposure.The expression of the androgen receptor (AR) was performed by confocal laser scanning microscope.RESULTS: FK228 killed LNCaP cells with an EC50 value of 7.4 ng/mL within 48 hours exposure as well as inducing cell apoptosis.FK228 could deplete AR in the nucleus.CONCLUSION: FK228 exhibits significant antitumor effect against LNCaP cells through depletion of AR.

Key words: histone deacetylase inhibitor, prostate cancer, androgen receptor, FK228, cell signaling pathway, apoptosis

CLC Number: